TSX gains back after eight-day rally snapped
Nektar Therapeutics (NASDAQ:NKTR) President and CEO Robin Howard W. sold 10,732 shares of common stock on September 4th and 5th, according to a new SEC filing. The sales, executed in multiple transactions, were priced between $32.37 and $39.89, netting a total of $430,958. The timing is notable as InvestingPro data shows NKTR trading near its 52-week high of $44.33, having surged over 150% in the past year.
The sales occurred in several tranches. On September 4, Robin Howard W. sold 1,923 shares at an average price of $32.37, 1,496 shares at $33.54, 613 shares at $34.40 and 1,134 shares at $35.80. On September 5, the CEO sold 3,304 shares at an average price of $37.87, 2,226 shares at $38.82 and 1,136 shares at $39.89. According to InvestingPro, the stock appears overvalued at current levels, with technical indicators suggesting overbought conditions.
Following these transactions, Robin Howard W. directly owns 56,008 shares of Nektar Therapeutics . The filing indicates that the transactions were made pursuant to a Rule 10b5-1 trading plan. With a market capitalization of $837.58 million, Nektar maintains a healthy balance sheet with liquid assets exceeding short-term obligations. For deeper insights into NKTR’s valuation and 15+ additional ProTips, check out the comprehensive Pro Research Report on InvestingPro.
In other recent news, Nektar Therapeutics reported a significant earnings miss for the second quarter of 2025, with an actual earnings per share (EPS) of -$2.78, far below the forecasted -$0.20. Despite this, the company’s revenue exceeded expectations, reaching $11.17 million compared to the anticipated $9.74 million. In related developments, Nektar’s shares experienced a notable increase after Sanofi released underwhelming clinical trial data for its amlitelimab treatment for atopic dermatitis. Analysts, including Yasmeen Rahimi from Piper Sandler, highlighted the competitive advantage of Nektar’s REZPEG drug, maintaining an overweight rating on the company. Rahimi emphasized REZPEG’s differentiated profile and its commercial potential across inflammatory diseases. The recent developments have positioned Nektar favorably in the market, according to analysts. These events have contributed to a positive market reaction for Nektar, despite the earnings miss.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.